773 related articles for article (PubMed ID: 31795353)
1. Multiple Functions of B Cells in the Pathogenesis of Systemic Lupus Erythematosus.
Ma K; Du W; Wang X; Yuan S; Cai X; Liu D; Li J; Lu L
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795353
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus.
Li Q; Wu H; Liao W; Zhao M; Chan V; Li L; Zheng M; Chen G; Zhang J; Lau CS; Lu Q
J Autoimmun; 2018 Sep; 93():1-15. PubMed ID: 30017673
[TBL] [Abstract][Full Text] [Related]
3. LRRK2 is involved in the pathogenesis of system lupus erythematosus through promoting pathogenic antibody production.
Zhang M; Yao C; Cai J; Liu S; Liu XN; Chen Y; Wang S; Ji P; Pan M; Kang Z; Wang Y
J Transl Med; 2019 Jan; 17(1):37. PubMed ID: 30670047
[TBL] [Abstract][Full Text] [Related]
4. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus.
Jenks SA; Cashman KS; Zumaquero E; Marigorta UM; Patel AV; Wang X; Tomar D; Woodruff MC; Simon Z; Bugrovsky R; Blalock EL; Scharer CD; Tipton CM; Wei C; Lim SS; Petri M; Niewold TB; Anolik JH; Gibson G; Lee FE; Boss JM; Lund FE; Sanz I
Immunity; 2018 Oct; 49(4):725-739.e6. PubMed ID: 30314758
[TBL] [Abstract][Full Text] [Related]
5. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
6. The expressions of Toll-like receptor 9 and T-bet in circulating B and T cells in newly diagnosed, untreated systemic lupus erythematosus and correlations with disease activity and laboratory data in a Chinese population.
Wu O; Chen GP; Chen H; Li XP; Xu JH; Zhao SS; Sheng J; Feng JB; Cai J; Fang XH; Zhang WH; Li LH; Zhang N; Li J; Li JJ; Pan FM; Wang CZ; Ye DQ
Immunobiology; 2009; 214(5):392-402. PubMed ID: 19362685
[TBL] [Abstract][Full Text] [Related]
7. MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus.
Ugarte-Berzal E; Boon L; Martens E; Rybakin V; Blockmans D; Vandooren J; Proost P; Opdenakker G
Front Immunol; 2019; 10():538. PubMed ID: 30967870
[TBL] [Abstract][Full Text] [Related]
8. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
Yap DYH; Chan TM
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
[TBL] [Abstract][Full Text] [Related]
9. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
10. B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6.
Jackson SW; Jacobs HM; Arkatkar T; Dam EM; Scharping NE; Kolhatkar NS; Hou B; Buckner JH; Rawlings DJ
J Exp Med; 2016 May; 213(5):733-50. PubMed ID: 27069113
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells in systemic lupus erythematosus.
Ohl K; Tenbrock K
Eur J Immunol; 2015 Feb; 45(2):344-55. PubMed ID: 25378177
[TBL] [Abstract][Full Text] [Related]
12. IL-10 producing regulatory and helper T-cells in systemic lupus erythematosus.
Geginat J; Vasco M; Gerosa M; Tas SW; Pagani M; Grassi F; Flavell RA; Meroni P; Abrignani S
Semin Immunol; 2019 Aug; 44():101330. PubMed ID: 31735515
[TBL] [Abstract][Full Text] [Related]
13. Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus.
De Groof A; Hémon P; Mignen O; Pers JO; Wakeland EK; Renaudineau Y; Lauwerys BR
Clin Rev Allergy Immunol; 2017 Oct; 53(2):181-197. PubMed ID: 28500565
[TBL] [Abstract][Full Text] [Related]
14. The IL-12-STAT4 axis in the pathogenesis of human systemic lupus erythematosus.
Ueno H
Eur J Immunol; 2020 Jan; 50(1):10-16. PubMed ID: 31762023
[TBL] [Abstract][Full Text] [Related]
15. T- and B-cell abnormalities in systemic lupus erythematosus.
Nagy G; Koncz A; Perl A
Crit Rev Immunol; 2005; 25(2):123-40. PubMed ID: 15952933
[TBL] [Abstract][Full Text] [Related]
16. B cell biology: implications for treatment of systemic lupus erythematosus.
Anolik JH
Lupus; 2013 Apr; 22(4):342-9. PubMed ID: 23553777
[TBL] [Abstract][Full Text] [Related]
17. Interferon
Akita K; Yasaka K; Shirai T; Ishii T; Harigae H; Fujii H
Front Immunol; 2020; 11():498703. PubMed ID: 33633721
[TBL] [Abstract][Full Text] [Related]
18. Systemic lupus erythematosus: all roads lead to type I interferons.
Pascual V; Farkas L; Banchereau J
Curr Opin Immunol; 2006 Dec; 18(6):676-82. PubMed ID: 17011763
[TBL] [Abstract][Full Text] [Related]
19. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors.
Christensen SR; Shlomchik MJ
Semin Immunol; 2007 Feb; 19(1):11-23. PubMed ID: 17276080
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus.
Dörner T; Szelinski F; Lino AC; Lipsky PE
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32675278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
